J. Sarkaria

Mark D Anderson, Jennie W. Taylor, Mark D. Anderson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.

J. Sarkaria, B. Scheithauer, J. Buckner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biopsy validation of 18 F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation : results of a prospective pilot study

Leland S. Hu, Jonathan M. Morris, J. Sarkaria, 2013 .

Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

J. Sarkaria, M. Yaszemski, A. V. van Wijnen, 2017, Biochemical and biophysical research communications.

Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts

Atique U. Ahmed, C. James, J. Sarkaria, 2022, Cancers.

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

Brett L Carlson, Jann N Sarkaria, J. Sarkaria, 2002, Cancer research.

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.

J. Sarkaria, J. Buckner, R. Rao, 2004, Current cancer drug targets.

Bioluminescent Imaging of Intracranial Vestibular Schwannoma Xenografts in NOD/SCID Mice

J. Sarkaria, E. Galanis, M. Link, 2009, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody

J. Ndungu, J. Snyder, D. Brat, 2015, Journal of drug targeting.

Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis

J. Sarkaria, S. Kesari, S. Burma, 2017, Nature neuroscience.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide

J. Sarkaria, M. Symons, Harshil Dhruv, 2016, Molecular Cancer Research.

Oral tongue cancer in young adults less than 40 years of age: Rationale for aggressive therapy

J. Sarkaria, P. Harari, 1994, Head & neck.

Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.

J. Sarkaria, P. Yue, J. Turkson, 2015, Journal of medicinal chemistry.

Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma

Leland S. Hu, J. Sarkaria, K. Swanson, 2019, bioRxiv.

Single-cell based elucidation of molecularly-distinct glioblastoma states and drug sensitivity

Evan O. Paull, Mariano J. Alvarez, J. Sarkaria, 2019, bioRxiv.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells

J. Sarkaria, Ella L. Kim, J. Prehn, 2017, Oncotarget.

Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells

J. Sarkaria, K. Krause, P. Walker, 2021, Communications biology.

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

Scott H. Kaufmann, Jann N. Sarkaria, J. Sarkaria, 2011, Proceedings of the National Academy of Sciences.

Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

J. Sarkaria, Y. Taya, R. Tibbetts, 1999, Cancer research.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling

J. Sarkaria, A. Vazquez, A. Hjelmeland, 2018, Cell Communication and Signaling.

Hypoxia-inducible factor 2α: a novel target in gliomas.

J. Sarkaria, R. Strowd, G. Lesser, 2018, Future medicinal chemistry.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Karl-Heinz Krause, Paul S Mischel, Kun-Liang Guan, 2017, Cancer cell.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma

J. Sarkaria, Minjee Kim, Shuangling Zhang, 2017, The Journal of Pharmacology and Experimental Therapeutics.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma

J. Sarkaria, J. Mosser, P. Decker, 2017, Clinical Cancer Research.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Lorenzo Trippa, Brian M Alexander, Paul S Mischel, 2015, Neuro-oncology.

Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake

Andrew E. Sloan, Jann N. Sarkaria, Robert J. Weil, 2013, Nature Neuroscience.

Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments

Susan M. Chang, J. Sarkaria, D. Sargent, 2011, Current oncology reports.

Misregulated E-Cadherin Expression Associated with an Aggressive Brain Tumor Phenotype

B. Necela, J. Sarkaria, B. Scheithauer, 2010, PloS one.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak

Yuan Qi, Jill P. Mesirov, Li Ding, 2010 .

Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Permalink

S. Gabriel, J. Mesirov, R. Wilson, 2010 .

H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers

J. Sarkaria, H. Gan, Zhiguo Zhang, 2018, eLife.

H3K27me3-mediated silencing of Wilms Tumor 1 supports the proliferation of brain tumor cells harboring the H3.3K27M mutation

J. Sarkaria, H. Gan, Zhiguo Zhang, 2017, bioRxiv.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.

Sabine Mueller, Haiyun Gan, Nalin Gupta, 2013, Genes & development.

Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme

D. Mukhopadhyay, J. Sarkaria, S. Dutta, 2020, Oncogene.

The histone H 3 . 3 K 27 M mutation in pediatric glioma reprograms H 3 K 27 methylation and gene expression

C. James, J. Sarkaria, S. Mueller, 2013 .

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Brett L Carlson, Jann N Sarkaria, C. James, 2009, Neuro-oncology.

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

J. Sarkaria, D. Schiff, R. Abounader, 2010, Anti-cancer agents in medicinal chemistry.

Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma

R. Verhaak, J. Sarkaria, B. O'neill, 2019, Clinical Cancer Research.

Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues

J. Sarkaria, K. Robertson, Jingxin Qiu, 2018, Genome Biology.

Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.

J. Sarkaria, R. Thompson, Wenbiao Chen, 2016, Neuro-oncology.

InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma

J. Sarkaria, R. Thompson, B. Mobley, 2015, Clinical Cancer Research.

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

C. James, J. Sarkaria, J. Uhm, 2005, Neuro-oncology.

The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation

J. Sarkaria, P. Kapranov, C. Wahlestedt, 2015, Proceedings of the National Academy of Sciences.

Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities

J. Sarkaria, S. Rosenfeld, P. Canoll, 2021, Cell reports.

Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery

J. Sarkaria, J. Pokorny, M. Schroeder, 2011, Current protocols in pharmacology.

EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion

J. Sarkaria, K. Gallo, Jian Chen, 2017, Molecular Cancer Research.

Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors.

Jesse S. Voss, J. Sarkaria, F. Meyer, 2019, Neuro-oncology.

Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.

A. Chinnaiyan, J. Sarkaria, P. Robertson, 2020, The Journal of clinical investigation.

Brain Tumor Stem Cell Multipotency Correlates with Nanog Expression and Extent of Passaging in Human Glioblastoma Xenografts

I. Weissman, J. Sarkaria, F. Meyer, 2013, Oncotarget.

Peak learning of mass spectrometry imaging data using artificial neural networks

Elizabeth C. Randall, T. Kapur, J. Sarkaria, 2021, Nature Communications.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Aaron S. Gajadhar, K. Aldape, J. Sarkaria, 2012, The Journal of clinical investigation.

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

J. Sarkaria, F. Meyer, Heping Wang, 2018, Nature Communications.

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

J. Sarkaria, P. Atadja, D. Wigle, 2008, Neuro-oncology.

Drug and disease signature integration identifies synergistic combinations in glioblastoma

Nicholas J. Lyons, Michael A. Durante, T. Golub, 2018, Nature Communications.

Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion

Mark A. Schroeder, Caterina Giannini, Jann N. Sarkaria, 2013, PloS one.

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas

C. James, J. Sarkaria, D. Scholtens, 2018, Clinical Cancer Research.

A Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Cetuximab and Radiation Therapy in Advanced Head and Neck Malignancies

Yol, Br, J. Sarkaria, 2012 .

Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

J. Sarkaria, F. Feng, D. Spratt, 2019, Neuro-oncology.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Susan M. Chang, D. Brat, J. Sarkaria, 2019, Neuro-oncology.

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors

J. Sarkaria, L. Drewes, W. Elmquist, 2020, Pharmaceutics.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

J. Sarkaria, Minjee Kim, Gautham Gampa, 2018, Pharmaceutical Research.

CNS Anticancer Drug Discovery and Development Conference White Paper.

D. Berry, J. Sarkaria, P. Wen, 2015, Neuro-oncology.

The role of LAT1 in 18F-DOPA uptake in malignant gliomas

J. Sarkaria, V. Lowe, T. Peterson, 2012, Journal of Neuro-Oncology.

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

J. Sarkaria, T. Waldman, P. Decker, 2012, Neuro-oncology.

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

J. Sarkaria, Liewei Wang, Minetta C. Liu, 2018, Breast cancer research : BCR.

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion

J. Sarkaria, Anna Jermakowicz, N. Ayad, 2021, Scientific Reports.

Using fluorodeoxythymidine to monitor anti‐EGFR inhibitor therapy in squamous cell carcinoma xenografts

Val J Lowe, Brett L Carlson, Jann N Sarkaria, 2008, Head & neck.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

Steven P. Angus, Laura E. Herring, C. Miller, 2017, Neuro-oncology.

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

J. Sarkaria, Liewei Wang, M. Goetz, 2021, Cancer Research.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Krishna R. Kalari, K. Kalari, J. Sarkaria, 2018, Molecular Cancer Therapeutics.

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process

J. Sarkaria, C. Ida, R. Jenkins, 2017, American journal of clinical pathology.

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma

J. Sarkaria, B. Scheithauer, F. Rodriguez, 2011, Acta Neuropathologica.

A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

J. Sarkaria, S. Kesari, S. Burma, 2017, Nature Neuroscience.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition

Webster K. Cavenee, Bob S. Carter, Oren J. Becher, 2015, Oncotarget.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis

J. Sarkaria, T. Fenton, W. Cavenee, 2012, Proceedings of the National Academy of Sciences.

Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity.

J. Sarkaria, R. Puri, E. Galanis, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Activation of Rac 1 by Src-dependent phosphorylation of Dock 180 Y 1811 mediates PDGFR a-stimulated glioma tumorigenesis in mice and humans

J. Sarkaria, T. Fenton, W. Cavenee, 2018 .

Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.

C. James, J. Sarkaria, Yan-li Hou, 2015, Neuro-oncology.

EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180

J. Sarkaria, W. Cavenee, F. Furnari, 2014, Oncogene.

Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans.

J. Sarkaria, T. Fenton, W. Cavenee, 2011, Journal of Clinical Investigation.

1 H 3 K 27 me 3-mediated silencing of Wilms Tumor 1 supports the proliferation of brain tumor cells harboring the H 3 . 3 K 27 M mutation

J. Sarkaria, H. Gan, Zhiguo Zhang, 2017 .

CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair.

F. Couch, J. Sarkaria, Liewei Wang, 2020, Blood.

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

D. Radisky, J. Sarkaria, Liewei Wang, 2021, Oncogene.

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex

J. Sarkaria, Kaushal Joshi, I. Nakano, 2012, Clinical Cancer Research.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Caterina Giannini, Jan C Buckner, Paul D Brown, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy

A. Chinnaiyan, J. Sarkaria, A. Rao, 2020, Molecular Cancer Therapeutics.

p53 isoform profiling in glioblastoma and injured brain

J. Sarkaria, D. Mastroeni, H. Scrable, 2013, Oncogene.

BIMG-20. METABOLIC BIOMARKERS IN MICRODIALYSATE OF IDH-1 MUTANT TUMORS

J. Sarkaria, W. Elmquist, T. Burns, 2021, Neuro-oncology Advances.

Localized metabolomic gradients in patient-derived xenograft models of glioblastoma.

Elizabeth C. Randall, Sankha S. Basu, J. Sarkaria, 2019, Cancer research.

High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.

J. Sarkaria, D. Petereit, J. Schink, 1999, International journal of radiation oncology, biology, physics.

Brain metastases-derived extracellular vesicles induce binding and aggregation of low-density lipoprotein

J. Sarkaria, Y. Talmon, Wan-Hsin Lin, 2020, Journal of Nanobiotechnology.

Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model

J. Sarkaria, B. Harley, H. Gaskins, 2020, bioRxiv.

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

J. Sarkaria, P. Decker, Shiv K. Gupta, 2019, Front. Oncol..

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

J. Sarkaria, P. Decker, G. Lomberk, 2012, Clinical Cancer Research.

ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL

Hu Li, J. Sarkaria, G. Arrigoni, 2020, Nature Communications.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

J. Sarkaria, J. Uhm, J. Buckner, 2015, Neuro-oncology.

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

C. James, J. Sarkaria, C. Erlichman, 2005, Neoplasia.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine

S. Gygi, J. Sarkaria, K. Ligon, 2018, Nature Communications.

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

J. Sarkaria, N. Curtin, W. Cliby, 2011, British Journal of Cancer.

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

J. Sarkaria, R. Abraham, L. Karnitz, 2000, Cancer research.

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

C. James, J. Sarkaria, E. Galanis, 2007, Molecular Cancer Therapeutics.

Src family kinases differentially influence glioma growth and motility

J. Sarkaria, F. Rodriguez, P. Anastasiadis, 2014, Molecular oncology.

Comparison between pulsed-field gel electrophoresis and the comet assay as predictive assays for radiosensitivity in fibroblasts.

J. Sarkaria, J. Yarnold, J. Peacock, 1998, Radiation research.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system

C. James, J. Sarkaria, A. Linninger, 2018, Neuro-oncology.

Gene Expression Profiling of NF-1-Associated and Sporadic Pilocytic Astrocytoma Identifies Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1) as an Underexpressed Candidate Biomarker in Aggressive Subtypes

Y. Asmann, J. Sarkaria, B. Scheithauer, 2008, Journal of neuropathology and experimental neurology.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition

J. Sarkaria, K. Pollok, M. Fishel, 2018, PloS one.

Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.

J. Sarkaria, K. Pollok, A. Safa, 2017, Journal of neurosurgery.

Purine metabolism regulates DNA repair and therapy resistance in glioblastoma

J. Sarkaria, A. Walker, T. Lawrence, 2020, Nature Communications.

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

J. Sarkaria, D. Gerber, S. Burma, 2019, Neuro-oncology.

ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain

J. Sarkaria, F. Lieberman, S. Chiou, 2010, Molecular Cancer Therapeutics.

Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor

J. Sarkaria, R. Strowd, G. Hawkins, 2020, Scientific Reports.

Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics

J. Sarkaria, C. Woese, B. Harley, 2017, MRS Communications.

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.

Brian A. Joughin, D. Lauffenburger, J. Sarkaria, 2017, Cancer research.

Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.

J. Sarkaria, D. Largaespada, W. Elmquist, 2015, Neuro-oncology.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

J. Sarkaria, K. Camphausen, P. Choyke, 2018, The Lancet. Oncology.

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

J. Sarkaria, Liewei Wang, F. White, 2020, Cancer Research.

Challenges in the Delivery of Therapies to Melanoma Brain Metastases

J. Sarkaria, S. Markovic, S. Vaidhyanathan, 2016, Current Pharmacology Reports.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

J. Sarkaria, J. Sludden, A. Boddy, 2015, Molecular Cancer Therapeutics.

EfficacyofPARP InhibitorRucaparib inOrthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

J. Sarkaria, J. Sludden, J. Murray, 2015 .

NT-113, A Novel, High CNS Penetrance pan-ERBB Inhibitor for Glioma Therapy

C. James, J. Sarkaria, T. Nicolaides, 2015 .

Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors

J. Sarkaria, 2006 .

Oncolytic measles virus strains have significant antitumor activity against glioma stem cells

J. Sarkaria, E. Galanis, M. Opyrchal, 2012, Gene Therapy.

Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer

Sumithra J Mandrekar, Steven E Schild, Jann N Sarkaria, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases

J. Sarkaria, S. Vaidhyanathan, W. Elmquist, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

J. Sarkaria, C. Wells, K. Pollok, 2017, Journal of neurosurgery.

Posttranscriptional regulation of PER1 underlies the oncogenic function of IREα.

J. Sarkaria, M. Hallett, F. Saltel, 2013, Cancer research.

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix

J. Sarkaria, T. Stehle, R. Sprangers, 2017, Proceedings of the National Academy of Sciences.

Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model

J. Sarkaria, W. Elmquist, J. Pokorny, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Efflux transporters at the blood-brain barrier limit delivery and efficacy of CDK4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model

J. Sarkaria, W. Elmquist, J. Pokorny, 2015 .

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

J. Sarkaria, P. Anastasiadis, Wan-Hsin Lin, 2021, bioRxiv.

Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases

J. Sarkaria, S. Vaidhyanathan, W. Elmquist, 2014, Drug Metabolism and Disposition.

Microsoft Word-22187792-file00.docx

J. Sarkaria, S. Vaidhyanathan, R. K. Mittapalli, 2014 .

CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair.

F. Couch, J. Sarkaria, Liewei Wang, 2020, Blood.

The adverse effect of treatment prolongation in cervical carcinoma.

J. Fowler, J. Sarkaria, D. Petereit, 1995, International journal of radiation oncology, biology, physics.

Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts*

Forest M White, Amanda M Del Rosario, Hannah Johnson, 2012, Molecular & Cellular Proteomics.

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.

C. James, J. Sarkaria, R. Rao, 2003, Frontiers in bioscience : a journal and virtual library.

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

J. Sarkaria, B. Karlan, A. Oberg, 2014, Clinical Cancer Research.

Molecular and Cellular Pathobiology Posttranscriptional Regulation of PER 1 Underlies the Oncogenic Function of IRE a

J. Sarkaria, E. Saltel, M. Hallett, 2013 .

Multimodal platform for assessing drug distribution and response in clinical trials.

Elizabeth C. Randall, Sankha S. Basu, J. Sarkaria, 2021, Neuro-oncology.

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.

Val J Lowe, Leland S. Hu, Caterina Giannini, 2013, Neuro-oncology.

Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?

J. Sarkaria, J. Buckner, N. Laack, 2015, Seminars in radiation oncology.

Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

J. Sarkaria, D. Kögel, J. Prehn, 2015, Front. Neurosci..

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

J. Sarkaria, K. Ballman, P. Decker, 2013, Neuro-oncology.

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

J. Sarkaria, J. Buckner, P. Brown, 2019, Journal of Neuro-Oncology.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

M. Prados, C. Miller, J. Sarkaria, 2018, Neuro-oncology.

Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group.

J. Sarkaria, M. Mehta, J. Buatti, 1995, International journal of radiation oncology, biology, physics.

Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy

J. Sarkaria, A. Iavarone, M. Sanson, 2023, Nature Cancer.

Complementary role of mathematical modeling in preclinical glioblastoma: differentiating poor drug delivery from drug insensitivity

J. Sarkaria, A. Hawkins-Daarud, S. Massey, 2021, bioRxiv.

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma

J. Sarkaria, S. Macura, Song Zhang, 2020, bioRxiv.

Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma

J. Sarkaria, B. Harley, S. Pedron, 2017, Advanced healthcare materials.

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma

Rebecca S. Lescarbeau, J. Sarkaria, P. Canoll, 2016, Molecular Cancer Therapeutics.

Quantitative Phosphoproteomics Reveals Wee 1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma Citation

Rebecca S. Lescarbeau, J. Sarkaria, P. Canoll, 2016 .

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

Elizabeth C. Randall, Aaron J. Johnson, Kristina B. Emdal, 2018, Nature Communications.

Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme

C. James, J. Sarkaria, E. Galanis, 2007, Clinical Cancer Research.

Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas

I. Weissman, J. Sarkaria, F. Meyer, 2020, BMC Cancer.

Pathogenic Germ Line Variants in a Patient With Severe Toxicity From Breast Radiotherapy.

J. Sarkaria, K. Corbin, T. Wilhite, 2019, Clinical breast cancer.

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells

J. Sarkaria, L. Samson, E. Kool, 2019, PloS one.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy

E. Thompson, J. Sarkaria, A. Oberg, 2018, Journal of the National Cancer Institute.

RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.

J. Sarkaria, J. Eckel-Passow, P. Decker, 2022, Neuro-Oncology.

Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases

J. Sarkaria, Minjee Kim, Gautham Gampa, 2019, The Journal of Pharmacology and Experimental Therapeutics.

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma

J. Sarkaria, C. Horbinski, Wenxia Wang, 2022, PloS one.

The efficacy of a ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma

J. Sarkaria, C. Horbinski, Wenxia Wang, 2021, bioRxiv.

Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

J. Sarkaria, R. Puri, E. Galanis, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

M. Berger, S. Vandenberg, M. Prados, 2008, Cancer research.

massNet: integrated processing and classification of spatially resolved mass spectrometry data using deep learning for rapid tumor delineation

Elizabeth C. Randall, T. Kapur, J. Sarkaria, 2021, bioRxiv.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

Elizabeth C. Randall, Aaron J. Johnson, Kristina B. Emdal, 2018, Nature Communications.

Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells.

J. Sarkaria, R. Bram, J. Choi, 2014, Cancer research.

Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies

J. Sarkaria, D. Lambrechts, R. Schiffelers, 2020, Cancers.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

J. Sarkaria, J. Buckner, B. Erickson, 2018, Cancer.

A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma.

J. Fowler, J. Sarkaria, D. Petereit, 1994, International journal of radiation oncology, biology, physics.

Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma

J. Sarkaria, S. Rosenfeld, J. Crish, 2020, Scientific Reports.

Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy

J. Sarkaria, Minjee Kim, Gautham Gampa, 2019, Drug Metabolism and Disposition.

msiPL: Non-linear Manifold and Peak Learning of Mass Spectrometry Imaging Data Using Artificial Neural Networks

William M. Wells, Tina Kapur, Forest M. White, 2020, bioRxiv.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Aaron J. Johnson, J. Sarkaria, J. Watters, 2018, Molecular Cancer Therapeutics.

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

J. Sarkaria, F. White, J. Eckel-Passow, 2021, Neuro-oncology.

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

C. James, J. Sarkaria, J. Uhm, 2008, Clinical Cancer Research.

LPA signaling is regulated through the primary cilium: a novel target in glioblastoma

J. Sarkaria, W. Geldenhuys, N. Margaryan, 2017, Oncogene.

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential 1 , 2

J. Sarkaria, L. Del Valle, F. Peruzzi, 2019 .

Intracellular Urokinase uPA-PAI-1 Complex: Disruption by Small Molecule Targets

Fredric, J. Sarkaria, N. Pasupuleti, 2018 .

CNS distribution of the ATM inhibitor AZD1390: Implications for the treatment of brain tumors

J. Sarkaria, W. Elmquist, Shiv K. Gupta, 2022, Journal of Pharmacology and Experimental Therapeutics.

Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma

J. Sarkaria, S. Rosenfeld, J. Crish, 2019, Scientific Reports.

Brain distribution of berzosertib: an ATR inhibitor for the treatment of glioblastoma.

J. Sarkaria, R. Bindra, Minjee Kim, 2021, The Journal of pharmacology and experimental therapeutics.

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

J. Sarkaria, M. Symons, J. Boockvar, 2021, Molecular medicine.

Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".

J. Sarkaria, M. D. de Gooijer, O. van Tellingen, 2020, Neuro-oncology.

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells

J. Sarkaria, C. Sereduk, N. Tran, 2019, Molecular medicine.

Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition

J. Sarkaria, Moses Rodriguez, S. Burma, 2020, bioRxiv.

GTP signaling links metabolism, DNA repair, and responses to genotoxic stress

J. Sarkaria, B. Győrffy, T. Lawrence, 2023, bioRxiv.

Influence of hyaluronic acid transitions in tumor microenvironment on glioblastoma malignancy and invasive behavior

J. Sarkaria, Yuhang Hu, B. Harley, 2018, bioRxiv.

EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma

J. Sarkaria, H. Varma, A. Charest, 2021, Oncogene.

Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Erik J Tryggestad, Matthew C Walb, Brett L Carlson, 2019, The British journal of radiology.

Quantifying glioblastoma drug penetrance from experimental data

J. Sarkaria, K. Swanson, S. Massey, 2019, bioRxiv.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling

J. Sarkaria, A. Vazquez, A. Hjelmeland, 2018, Cell Communication and Signaling.

Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor

J. Sarkaria, Minjee Kim, Shuangling Zhang, 2021, Drug Metabolism and Disposition.

Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models

J. Sarkaria, C. Howe, W. Elmquist, 2021, Journal of Neuroscience Methods.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

J. Sarkaria, Minjee Kim, Gautham Gampa, 2018, Pharmaceutical Research.

Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells

J. Sarkaria, K. Krause, P. Walker, 2021, Communications Biology.

Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.

C. N. Coleman, J. Sarkaria, M. Mehta, 2013, Journal of the National Cancer Institute.

Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

J. Sarkaria, H. Phillips, S. Kharbanda, 2012, Clinical Cancer Research.

Abstract C191: The effect of the cyclin‐dependent kinase inhibitor PD 0332991 on glioblastoma cells and relationship with p15INK4B/p16INK4A expression

J. Sarkaria, R. Jenkins, L. Cen, 2009 .

Title. Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.

J. Sarkaria, M. Rees, A. Pyle, 2023 .

NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

C. James, J. Sarkaria, N. Butowski, 2014, Molecular Cancer Therapeutics.

Small Molecule Therapeutics NT 113 , a Pan-ERBB Inhibitor with High Brain Penetrance , Inhibits the Growth of Glioblastoma Xenografts with EGFR Ampli fi cation

C. James, J. Sarkaria, N. Butowski, 2014 .

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

J. Sarkaria, D.J. Daniels, Julian S. Rechberger, 2023, Biomedicines.

Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

M. Berger, C. James, J. Sarkaria, 2007, Journal of neurosurgery.

Dosimetric Patterns of Failure in the Era of Novel Chemoradiotherapy in Newly-Diagnosed Glioblastoma Patients.

J. Sarkaria, P. Brown, E. Galanis, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA

Leland S. Hu, J. Sarkaria, J. Uhm, 2018, Neuro-Oncology.

PATH-47. CLINICAL SENSITIVITY AND SPECIFICITY OF ILLUMINA METHYLATION ARRAY FOR CLASSIFYING ADULT GLIOMAS INTO WHO GROUPS

J. Sarkaria, J. Eckel-Passow, P. Decker, 2017 .

Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas

J. Sarkaria, Moses Rodriguez, B. Himes, 2023, Communications Biology.

How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors

J. Sarkaria, W. Elmquist, Surabhi Talele, 2023, Pharmaceutical research.

CNS delivery of the DNA-PKcs inhibitor peposertib as radiosensitizer for brain metastases.

J. Sarkaria, W. Elmquist, Surabhi Talele, 2022, Journal of Pharmacology and Experimental Therapeutics.

Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma

J. Sarkaria, R. Bindra, Minjee Kim, 2021, Journal of Pharmacology and Experimental Therapeutics.

Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model

J. Sarkaria, B. Harley, H. Gaskins, 2020, Journal of Neuroinflammation.

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

J. Sarkaria, Liewei Wang, Minetta C. Liu, 2018, Breast Cancer Research.

Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts

J. Sarkaria, D. Raucher, L. Dhungel, 2023, Bioengineering.

Initial results of a phase II trial of 18F-DOPA PET-guided dose-escalated radiotherapy for glioblastoma.

J. Sarkaria, J. Uhm, V. Lowe, 2021, International journal of radiation oncology, biology, physics.

The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot).

M. Lindstrom, J. Fowler, J. Sarkaria, 1995, International journal of radiation oncology, biology, physics.

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models

J. Sarkaria, N. Agar, P. Decker, 2023, Neuro-oncology advances.

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential12

J. Sarkaria, F. Peruzzi, M. Rak, 2019, Translational oncology.

Abstract 4476: Cytotoxicity of a novel bi-functional temozolomide analog, DP68, is independent of MGMT status in glioblastoma models.

J. Sarkaria, R. Wheelhouse, R. Phillips, 2013 .

The Impact of Hemi-brain Irradiation on Accumulation of PI3K/mTOR Inhibitors With Limited (GDC-0980) and Robust (GNE-317) Blood–Brain Barrier Penetration

J. Sarkaria, T. Sio, K. Furutani, 2014 .

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

J. Sarkaria, M. Symons, J. Boockvar, 2019, Molecular Medicine.

Identify non-mutational p53 functional deficiency in human cancers

J. Sarkaria, A. Oberg, D. Kozono, 2023, bioRxiv.

Glycan Node Analysis Detects Varying Glycosaminoglycan Levels in Melanoma-Derived Extracellular Vesicles

J. Sarkaria, Y. Talmon, C. Borges, 2023, International journal of molecular sciences.

Matrix hyaluronic acid and hypoxia influence a CD133+ subset of patient-derived glioblastoma cells.

J. Sarkaria, B. Harley, J. Chen, 2021, Tissue engineering. Part A.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

J. Sarkaria, K. Camphausen, P. Choyke, 2018, The Lancet. Oncology.

A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas

J. Sarkaria, J. Akers, B. Carter, 2014, Oncotarget.

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix

J. Sarkaria, T. Stehle, R. Sprangers, 2017, Proceedings of the National Academy of Sciences.

Main Manuscript for Cell migration simulator-based biomarkers for glioblastoma

J. Sarkaria, D. Odde, Jay Hou, 2023, bioRxiv.

Differential H2O2 Metabolism among Glioblastoma Subtypes Confers Variable Responses to Pharmacological Ascorbate Therapy Combined with Chemoradiation

J. Sarkaria, K. Mapuskar, M. Petronek, 2023, International journal of molecular sciences.

Title : Brain distribution of berzosertib : an ATR inhibitor for the treatment of glioblastoma

J. Sarkaria, R. Bindra, Minjee Kim, 2021 .

Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization

J. Sarkaria, B. Harley, W. Elmquist, 2024, Science Translational Medicine.

DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.

J. Sarkaria, N. Agar, R. Bindra, 2024, Neuro-oncology.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

J. Sarkaria, K. Ballman, Wenting Wu, 2013, Neuro-oncology.

Efficacy of Protracted Temozolomide Dosing Is Limited in Mgmt Unmethylated Gbm Xenograft Models Neuro-onco Lo Gy Materials and Methods Results Initial Comparison of Tmz Dosing Regimens

J. Sarkaria, K. Ballman, J. Pokorny, 2022 .